NewsRx

Search our medical news database

Drug Delivery (HBV)

Lipid Prodrugs May Be Useful in Chronic Hepatitis

Published in Hepatitis Weekly, June 10th, 1996

Lipid prodrugs which target the liver may be useful in the treatment of patients with chronic hepatitis.

In woodchuck studies, researcher Brent A. Korba et al. found that these phosphatidyl-dideoxyguanosines had enhanced antiviral activity over dideoxyguanosine alone in hepatitis therapy.

A number of nucleosides have been found to inhibit hepatitis B virus (HBV) replication in vitro. Recently lamivudine (3TC) was shown to be effective in chronic hepatitis B in a double-blind, randomized clinical study. After three months of treatment at a dosage of 100 mg/kg/day, all patients exhibited undetectable serum levels of HBV DNA. Serum HBV DNA reappeared...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook